User:Jmo7865/sandbox

Welcome to your sandbox! HAAAAAY!!!

Link to Project Resource Page
Project Homepage and Resources

Practice Editing Here (Nov 15th in-class Wiki session work)

 * This is a place to practice clicking the "edit" button and practice adding references (via the citation button).

Task:


 * 1) Find a peer-reviewed journal article on PubMed. Practice inserting your citation in the above space using the "cite" tool
 * 2) Choose one "B-level" medical article on Wikipedia from the following list: https://wp1.openzim.org/#/project/Medicine/articles?quality=B-Class&importance=High-Class
 * 3) Practice editing live on Wikipedia by finding a typo in the text or improving the clarity/readability of a sentence by adjusting a few words in a sentence.

Assignment # 3- please post an anonymous copy here!
New drug therapies include diflunisal, inotersen, and patisiran.
 * Suggested Change #7: Original: However, newer therapies including diflunisal, an anti-inflammatory drug, and inotersen and patisiran, drugs which prevent misfolded protein formation, have shown early promises in slowing disease progression.[29] The latter two drugs have shown their benefit in neurological impairment scores and quality of life measures.[29] However, their role in cardiac ATTR amyloidosis is still being investigated.[29] Suggested Change: New drug therapies include diflunisal, inotersen, and patisiran.  Diflunisal binds to misfolded mutant TTR protein to prevent its buildup, like how tafamidis works. Low-certainty evidence indicates that it reduces worsening of peripheral neuropathy and disability from disease progression. (Magrinelli)  Inotersen blocks gene expression of both wild-type and mutant TTR, reducing amyloid precursor. Moderate-certainty evidence suggests that it reduces worsening of peripheral neuropathy. Long-term efficacy and safety of inotersen use in people with mutant TTR-related amyloidosis is still being evaluated in a phase-3 clinical trial as of 2021. Both diflunisal and inotersen may also reduce decreases in quality-of-life, though the evidence for this effect is yet unclear (Magrinelli). For people with cardiac ATTR the effect of inotersen use is inconclusive and requires further investigation. (Marques)  Patisiran functions similarly to inotersen. Moderate-certainty evidence suggests that patisiran reduces worsening of peripheral neuropathy and disability from disease progression. Additionally, low-certainty evidence suggests that patisiran reduces decreases in quality-of-life and slightly reduces the rate of adverse events versus placebo. There is no evidence of an effect on mortality rate (Magrinelli). A review of early data from use of patisiran in people with variant cardiac ATTR suggests that it may reduce mortality and hospitalization, however this is still being investigated and requires (Marques)

Diflunisal binds to misfolded mutant TTR protein to prevent its buildup, like how tafamidis works. Low-certainty evidence indicates that it reduces worsening of peripheral neuropathy and disability from disease progression. (Magrinelli)

Inotersen blocks gene expression of both wild-type and mutant TTR, reducing amyloid precursor. Moderate-certainty evidence suggests that it reduces worsening of peripheral neuropathy. Long-term efficacy and safety of inotersen use in people with mutant TTR-related amyloidosis is still being evaluated in a phase-3 clinical trial as of 2021. Both diflunisal and inotersen may also reduce decreases in quality-of-life, though the evidence for this effect is yet unclear. (Magrinelli). For people with cardiac ATTR the effect of inotersen use is inconclusive and requires further investigation. (Marques)

Patisiran functions similarly to inotersen. Moderate-certainty evidence suggests that patisiran reduces worsening of peripheral neuropathy and disability from disease progression. Additionally, low-certainty evidence suggests that patisiran reduces decreases in quality-of-life and slightly reduces the rate of adverse events versus placebo. There is no evidence of an effect on mortality rate .(Magrinelli). A review of early data from use of patisiran in people with variant cardiac ATTR suggests that it may reduce mortality and hospitalization, however this is still being investigated and requires (Marques)

Amyloidosis

What to post on the Wikipedia article talk page (part of assignment 3)

 * This will also be covered on Nov 15th in class. Your group should use the below template to share an outline of your proposed improvements (including your new wording and citations). Article talk pages are not places to share your assignment answers. The Wikipedia community will be more interested in viewing your exact article improvement suggestions including where you plan to improve the article (which section), what wording you suggest, and the exact citation (Note: all citations must meet WP:MEDRS)
 * You will not be able to paste citations directly from your sandbox to talk pages (unless you are interested in editing/learning Wiki-code in the "source editing" mode). We suggest re-adding your citations on the talk page manually (using the cite button and populating the citation by pasting in the DOI, website, or PMID). You will have to repeat this process yet again when you edit the actual article live.
 * HELP CARL IS SO HARD!
 * Talk Page Template: CARL Medical Editing Initiative/Fall 2021/Talk Page Template